Replies to post #481242 on NorthWest Biotherapeutics Inc (NWBO)

[Poor Man -]

Licensing is an option of course, and perhaps a better alternative to expedite the development of Direct along an array of indications. As far as NWBO as a subsidiary, that doesn’t provide much benefit.

NWBO is not an existing operating company per se, it’s just an investment vehicle for Toucan. A buyer would just be acquiring the rights to the IP and assignment of existing contracts and regulatory approvals.

[biosectinvestor]

Exactly right Gary, most of the inventive and advanced work in biotech is being done by small bios that are taking all the risk with the help of small, retail investors. It’s quite a ridiculous situation, but big capitalized firms don’t like risk when they can sit on 100 year old discoveries like insulin, and just raise the prices and let the massive billions in revenue just roll in.

Big Pharma is not exactly the most innovative set of entrepreneurs in biotech. They mostly just steal for cheap from the farms of small firms they like to keep in a distressed state unless they sell out early.